Mesalazine associated nephrogenic diabetes insipidus presenting as weight loss.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 1582604.
- Also identified by PMC identifier 1374079.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Nephrotoxicity in association with 5-aminosalicylic acid therapy is well recognised. In this patient the nephrotoxicity only became apparent after severe weight loss had occurred in association with nephrogenic diabetes insipidus. The patient aged 26 with ulcerative colitis received resin coated mesalazine (Asacol) 1200 mg/day and lost 12 kg in weight over a four month period, only complaining of thirst towards the end of this period.
Medical subject headings
- Aminosalicylic Acids
- Diabetes Insipidus
- Nephritis, Interstitial
- Weight Loss